HOME (首页)www.epgonline.orgDRUGS (医学数据)www.epgonline.orgDISEASE KNOWLEDGE (教育)www.epgonline.orgGUIDELINES (医疗指南)www.epgonline.orgTRIALS (临床试验)
Members
Username/Email

Password



EPG News Feed Medical News
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Frequent Searches:
Search
Languages

Medical News Headlines
Thrombosis risk may be raised by cancer drugs
Cancer patients receiving drugs to lower the risk of anaemia...
Published Tuesday 01 December 2009

Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have...
Published Tuesday 01 December 2009

Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a...
Published Monday 30 November 2009

Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more...
Published Sunday 29 November 2009

More Medical News
Languages

HPV & Cervical Cancer

Please note- The EPG HPV and Cervical Cancer Knowledge Centre is for Doctors and other Healthcare Professionals.

Worldwide, every two minutes a woman dies of cervical cancer. Globally, cancer of the cervix is the second most prevalent cancer in women, causing nearly 500,000 new cases per year, and the third leading cause of female cancer deaths after breast and lung cancer (Ferlay et al 2004).

HPV & Cervical Cancer Knowledge Centre

There are over 100 types of human papillomavirus (HPV), of which 30-40 can infect mucosal tissue. The others cause a variety of non-genital conditions, such as plantar warts (Wilson 2001; Burd 2003; von Krogh 2001). Of the types that can infect mucosal tissue, there are low-risk HPV types that can cause benign, low-grade lesions on the cervical surface or genital warts (which rarely progress to cancer). More importantly, there are over 15 oncogenic types that have been directly linked to cervical cancer (Bosch et al 2002; Schiller and Davies 2004; Muñoz et al 2003). Of these oncogenic HPV types, HPV 16 and 18 are the most important and are found in over 70% of cervical cancers globally (Muñoz et al 2004).

HPV is a very common and easily transmittable virus. The risk of contracting HPV starts with the first sexual encounter and lasts throughout a woman’s sexually active life. Infection does not require full penetrative intercourse, as skin-to-skin contact in the genital area is enough to spread the infection. Condoms do not fully protect from cervical cancer (Schiffman and Kjaer 2003; Burd 2003).

Virtually all cases of cervical cancer are associated with HPV infection (Bosch et al 2002). 

Given the significant burden associated with cervical cancer, prevention and treatment strategies are critical (Franceschi 2005; Franco et al 2001). Proper screening requires well-organised acquisition of cervical samples at regular intervals (Sankaranarayanan et al 2005). This identifies abnormal cells on the cervix, which can be removed, if treatment is necessary. 

Cervical screening is currently the only strategy for early detection of cervical abnormalities and HPV infections.

Enter the HPV & Cervical Cancer Knowledge Centre

What’s in the HPV & Cervical Cancer Knowledge Centre?

DISEASE KNOWLEDGE 教育 – evidence based education and clinical tools written for doctors and physicians
More Results Drugs Relating To cervical cancer

  • CERVARIX - 51.32%
    CERVARIX is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. The indication is based on demonstration of efficacy in women aged 15-25 years following vaccination with ...


  • GARDASIL - 51.32%
    Gardasil is a vaccine for the prevention of premalignant genital lesions (cervical, vulvar and vaginal), cervical cancer and external genital warts (condyloma acuminata) causally related to Human Papillomavirus (HPV) types 6, 11, 16 and 18. The indication is based on the demonstration of efficacy of ...


  • Cisplatin - 41.35%
    Cisplatin has antitumour activity either as a single agent or in combination chemotherapy particularly in the treatment of testicular and metastatic ovarian tumours, also cervical tumours, lung carcinoma and bladder cancer ...


  • Gemcitabine 200mg Powder for Solution for Infusion - 26.38%
    Bladder Cancer: Locally advanced or metastatic bladder cancer in combination with cisplatin. Breast Cancer: Locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. The preceding chemotherapy should have ...


  • Mitomycin - 26.21%
    ... agent and in combination in liver cancer when given by the intra-arterial route. 6. It has a possible role in combination with other cytotoxic drugs in colo-rectal cancer. 7. It shows a degree of activity as a single agent or part of combination therapy in cancer of the head and neck. 8. It shows a ...


  • TAXOTERE - 25.58%
    ... cancer TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. TAXOTERE in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer ...


FEATURES

DRUG UPDATES Drug updates feed

EMAIL BULLETIN

DISEASE CENTRES Disease Centres feed

MEDICAL NEWS EPG News Feed

RESEARCH

GOOGLE SEARCH

GUIDELINES UK Drug Data Feed

Medicine 医学 UK Drug Data Feed